Related Experiment Video
Updated: Jul 30, 2026
12:44
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Splenic angiosarcoma: a clinicopathologic and immunophenotypic study of 28 cases
T S Neuhauser1, G A Derringer, L D Thompson
1Department of Hematopathology, Armed Forces Institute of Pathology, Washington, DC, USA. Thomas.Neuhauser@59MDW.WHMC.AF.MIL
Summary
Primary splenic angiosarcoma is a rare, aggressive cancer. This study characterized 28 cases, finding it almost universally fatal with frequent metastases and co-expression of endothelial and histiocytic markers.
Area of Science:
- Oncology
- Pathology
- Vascular Biology
Background:
- Primary splenic angiosarcoma is a rare neoplasm with limited characterization.
- Understanding its clinical, morphological, and immunophenotypic features is crucial for diagnosis and management.
Purpose of the Study:
- To characterize the clinical, morphological, and immunophenotypic findings of primary splenic angiosarcoma.
- To investigate the origin and aggressive nature of this rare splenic tumor.
Main Methods:
- Retrospective analysis of 28 primary splenic angiosarcoma cases.
- Clinical data review, macroscopic and microscopic examination.
- Immunohistochemical analysis using a panel of vascular and histiocytic markers.
Main Results:
- The majority of patients presented with abdominal pain and splenomegaly; 25% had splenic rupture.
- Tumors were heterogeneous, showing vasoformative components with atypical endothelial cells, often with hemorrhage and necrosis.
- Immunohistochemistry revealed co-expression of endothelial (CD34, FVIIIRAg, VEGFR3, CD31) and histiocytic (CD68, lysozyme) markers in most cases.
- 100% of patients developed metastases, and the neoplasm was almost universally fatal despite aggressive therapy.
Conclusions:
- Primary splenic angiosarcoma is an extremely aggressive neoplasm with a universally fatal outcome.
- Co-expression of histiocytic and endothelial markers suggests a possible origin from splenic lining cells.
- Further research into targeted therapies is warranted for this rare and aggressive malignancy.
